- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04817072
Evaluation of Mood Disorders Under Biologics in Chronic Inflammatory Rheumatic Disease (EMOTION)
April 5, 2022 updated by: Centre Hospitalier Universitaire de Besancon
Evaluation of Mood Disorders Under Biologics (Anti-TNF Alpha) in Chronic Inflammatory Rheumatic Disease
Chronic inflammatory rheumatic diseases (CIRD) affect many organ systems.
Painful sensations within the joints spine, hand and foot deformities, low quality of life and psychosocial status in patients with rheumatoid arthritis, spondyloarthritis and psoriatic arthritis can lead to the development of anxiety and depression.
Prevalences of anxiety increase in patients suffering of CIRD, compared with healthy individuals.
Another connection has been identified by the links between depression and systemic inflammation.
It is proven that higher plasma levels of pro-inflammatory cytokines such as tumor necrosis factor alpha (TNFa) affect neurotransmitter metabolism, with influence on patients mood.
The purpose of EMOTION study is therefore to analyze thymic variation under TNFa therapy, as treatment of CIRDs.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
108
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Charline Vauchy, PhD
- Phone Number: +333 81 21 88 75
- Email: cvauchy@chu-besancon.fr
Study Contact Backup
- Name: Magali Nicolier-Pallandre, PhD
Study Locations
-
-
-
Besançon, France, 25000
- Recruiting
- University Hospital
-
Contact:
- Charline VAUCHY
-
Principal Investigator:
- Eric Toussirot, PU-PH
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 80 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Adult patients (≥18 ; ≤ 80)
- Patient with rheumatoid arthritis (RA) according to the ACR 2010 criteria, axial or peripheral spondyloarthritis (SpA) according to ASAS criteria, ankylosing spondylitis (AS) according to the New York criteria or psoriatic arthritis (PsA) according to CASPAR criteria
- Signature of informed consent
- Affiliation to a French social security or receiving such a scheme
Exclusion Criteria:
- Patient having previously received anti-TNFα treatment
- Patient with previously diagnosed depressive or psychiatric pathology and / or receiving anti-depressant treatment
- Subjects with limited legal capacity.
- Subjects judged by the investigator to be unlikely to comply with study procedures
- Subjects with no social security coverage.
- Pregnant women.
- Subjects still in the exclusion period of another study, or according to the national registry of clinical trial participants.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Chronic inflammatory rheumatic disease
Patients presenting a chronic inflammatory rheumatic disease (rheumatoid arthritis, spondyloarthritis or psoriatic arthritis), requiring anti-TNFa therapy and with a QIDS SR-16 (QIDS-SR 16-Quick Inventory of Depressive Symptomatology-Self Reported 16 items) score between 6 and 19
|
Blood sample (20mL) for pro-inflammatory cytokines assay
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Severity of depressive symptoms
Time Frame: 1 month after initiation of anti-TNFa therapy
|
Score achieved on the validated self-report questionnaire (QIDS SR16) evaluating the severity of depressive symptoms
|
1 month after initiation of anti-TNFa therapy
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Evaluation of disease activity
Time Frame: 3 months after initiation of anti-TNFa therapy
|
Evaluation with CPDAI (Composite Psoriatic Disease Activity Index) (minimum value: 0; maximum value: 15; increases with the activity of the disease)
|
3 months after initiation of anti-TNFa therapy
|
Evaluation of disease activity
Time Frame: 3 months after initiation of anti-TNFa therapy
|
Evaluation with DAS28 (Disease Activity Score 28-joint count) (minimum value: 0; maximum value: 9.4; increases with the activity of the disease)
|
3 months after initiation of anti-TNFa therapy
|
Evaluation of disease activity
Time Frame: 3 months after initiation of anti-TNFa therapy
|
Evaluation with BASDAI (Bath Ankylosing Spondylitis Disease Activity Index) (minimum value: 0 (no disease activity); maximum value: 10 (very active disease))
|
3 months after initiation of anti-TNFa therapy
|
Evaluation of disease activity
Time Frame: 3 months after initiation of anti-TNFa therapy
|
Evaluation with ASDAS (Ankylosing Spondylitis Disease Activity Score) (minimum value: 0 (no disease activity); value >3.5 between : very high disease activity)
|
3 months after initiation of anti-TNFa therapy
|
Evaluation of Fatigue
Time Frame: 3 months after initiation of anti-TNFa therapy
|
Evaluation with Functional Assessment of Chronic Illness Therapy
|
3 months after initiation of anti-TNFa therapy
|
Evaluation of Pleasure
Time Frame: 3 months after initiation of anti-TNFa therapy
|
Evaluation with Snaith-Hamilton pleasure scale (minimum value: 0 (no disease activity); maximum value: 14 (very active disease)).
A higher total SHAPS score indicated higher levels of anhedonia.
|
3 months after initiation of anti-TNFa therapy
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Eric Toussirot, PU-PH, Besançon University Hospital
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
May 19, 2021
Primary Completion (Anticipated)
May 1, 2024
Study Completion (Anticipated)
September 1, 2024
Study Registration Dates
First Submitted
January 29, 2021
First Submitted That Met QC Criteria
March 24, 2021
First Posted (Actual)
March 25, 2021
Study Record Updates
Last Update Posted (Actual)
April 8, 2022
Last Update Submitted That Met QC Criteria
April 5, 2022
Last Verified
April 1, 2022
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- P/2019/462
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Mood Disorders
-
Université du Québec a MontréalCiusss de L'Est de l'Île de Montréal; PhysioExtra; EnergirRecruitingDepression ; Anxiety With Depressed Mood ; Mood Disorder, Adjustment Disorder With Depressed MoodCanada
-
Joliet Center for Clinical ResearchAbbottCompleted
-
National Institute of Mental Health (NIMH)Completed
-
National Institute of Mental Health (NIMH)Completed
-
University of North Carolina, Chapel HillNational Institute of Mental Health (NIMH)Completed
-
University of Colorado, DenverCompletedMood Disorders | Irritable MoodUnited States
-
VA Office of Research and DevelopmentCompleted
-
Baskent UniversityZİYAFET UĞURLURecruitingDisaster; Personality | Disorder, MoodTurkey
-
Fayoum University HospitalCompletedKetamine-Induced Mood DisorderEgypt
-
Mayo ClinicCompletedMood Disorders in Children and AdolescentsUnited States
Clinical Trials on Blood sample
-
Memorial Sloan Kettering Cancer CenterActive, not recruiting
-
Medical University of WarsawCompletedArthroplasty | Platelet Aggregation | Methylmethacrylate EmbolismPoland
-
First Affiliated Hospital of Zhejiang UniversityRecruitingComplication | Hematologic Malignancy | Hematopoietic Stem Cell Transplantation | Chronic Graft-versus-host-diseaseChina
-
University Hospital, BordeauxMinistry for Health and Solidarity, FranceRecruitingImmune Thrombocytopenia | Autoimmune Hemolytic Anemia | Autoimmune NeutropeniaFrance
-
University Hospital, ToursCompletedMetastatic Prostate Cancer | Circulating Tumor DNAFrance
-
University Hospital, BordeauxActive, not recruitingSystemic Lupus Erythematosus | Systemic SclerodermaFrance
-
University Hospital, BordeauxCompletedRenal Function Disorder | Chronic Renal Diseases
-
Meir Medical CenterCompleted
-
Centre Hospitalier Universitaire de NīmesNot yet recruitingNarcolepsy Type 1 | Bacterial TranslocationFrance
-
The First Affiliated Hospital of Soochow UniversityRecruitingGraft Vs Host DiseaseChina